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a b s t r a c t
We describe the ﬁrst clinical case of cryptococcosis due C. gattii in a Cuban immunocompetent patient
who had a traveling history two years before to Central America. Molecular characterization of the
isolate showed it to be genotype AFLP5 of which MLST sequences clustered with clinical and
environmental strains from Colombia. The patient died one year after the diagnosis despite a prolonged
treatment with (liposomal) amphotericin B, ﬂuconazole, voriconazole and gamma interferon.
& 2013 International Society for Human and Animal Mycology. Published by Elsevier B.V
1. Introduction
Cryptococcosis is a life-threatening mycosis that develops
following the inhalation and dissemination of fungal conidia
and/or desiccated yeast forms. The Cryptococcus neoformans/
Cryptococcus gattii species complex are free-living saprophytic
yeasts which can survive in diverse niches [1]. The complex
includes two species with their varieties and serotypes: C. neofor-
mans var. grubii (serotype A; genotype AFLP1), C. neoformans var.
neoformans (serotype D; genotype AFLP2) and the intervarietal
state C. neoformans serotype AD (genotype AFLP3), which mostly
affect immunocompromised patients worldwide; the other
species, C. gattii (serotypes B and C; genotypes AFLP4-7 and
AFLP10) mainly affects individuals without apparent alterations
of the immune system and used to have a more restricted
distribution to tropical and subtropical climates, although recent
ﬁndings indicates a drastic change in the adaptation of this
organism to other environments [2–4]. Up to now, only C. neoformans
var. grubii has been routinely isolated from environmental and
human clinical samples in Cuba [5,6]. Here we report a fatal case of
C. gattii meningitis in Cuba in an immunocompetent patient.
2. Case
A 56-year-old white Cuban male from Villa Clara, a city in the
central part of the island, who had no signiﬁcant medical history,
was admitted on July 5th 2011 because of mild fever, myalgia,
malaise and diffuse headache. He was a moderate smoker and
used only sporadically alcohol. His most recent travel history was
to Honduras (2003–2005) and Guatemala (2007–2009) where he
worked as a general practitioner. Physical examination revealed a
mild fever of 38 1C, signs of lung consolidation on the lower right
side, and ﬁne crackles with chest auscultation. A chest radiograph
showed an inﬂammatory lesion on the lower right side consistent
with pneumonia. No cultures or clinical chemical investigations
were performed. The patient was treated empirically with peni-
cillin but after seven days (July 12th, 2011) he was admitted to
the local hospital because of worsening of his general condition
and development of a severe headache. Hematologic and serolo-
gic tests, including HIV antibody screening, were negative. A
lumbar puncture showed a high opening pressure (40 cm H2O)
and cerebrospinal ﬂuid (CSF) analysis revealed pleocytosis (215
cells/mm3 predominantly lymphocytes), reduced glucose level
(2.6 mg/dL) and elevated protein level (480 mg/dL) (Table 1).
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Sputum and CSF was cultured and treatment was started with
ceftriaxone (4 g/d). After isolation of Klebsiella pneumoniae from
sputum cultures, amikacin (15 mg/kg/d during seven days) was
added to the treatment. The patient did not improve satisfactorily
and therefore a computerized tomography (CT) scan and mag-
netic resonance imaging (MRI) were performed which were
unremarkable. To reduce suspected intracranial hypertension,
the lumbar puncture was repeated a week later (July 20th,
2011). Opening pressure was still increased with signs of inﬂam-
mation (Table 1). Direct microscopic examination of CSF with
India ink showed the presence of a large number of rounded and
encapsulated yeasts compatible with Cryptococcus. The treatment
was changed to amphotericin B deoxycholate (0.7 mg/kg) intrave-
nously and 400 mg (b.i.d.) of ﬂuconazole orally. Flucytosine was
not available in Cuba. After an initial improvement with antifungal
treatment the patient experienced worsening pulmonary functions,
intense headache, neurological impairment, decreased visual acuity
and hearing loss on the right side. Therefore on August 23th, 2011,
the patient was transferred to an infectious diseases reference center
in Havana where the isolate was identiﬁed as Cryptococcus gattii. In
vitro susceptibility testing showed low MICs of amphotericin B
(0.125 mg/L), ﬂuconazole (2 mg/L), ﬂucytosine (0.5 mg/L), itracona-
zole (0.125 mg/L), posaconazole (0.125 mg/L), voriconazole
(0.063 mg/L) and isavuconazole (0.016 mg/L).
So far the patient had received a cumulative dose of 1.500 mg
amphotericin B deoxycholate and his kidney functions had
become slightly disturbed (creatinine 130 mmol/L, ureum
10.6 mmol/L). Mayor ﬁndings at physical examination revealed
a right VI cranial nerve palsy, blurred vision and diplopia in
addition to a non-resolving pneumonia. Repeat CT scan with and
without contrast did not show signs of cerebral edema or other
abnormalities. Because of the poor clinical response and worsen-
ing kidney function amphotericin B deoxycholate was changed to
liposomal amphotericin B (3 mg/kg) and ﬂuconazole 800 mg/d
was continued from August 29th to October 6th, 2011, but again
without clinical improvement. Several lumbar punctures were
necessary to control high intracranial pressure. All samples
remained microscopically positive for cryptococci (Table 1). In
this period the patient became blind and lost his hearing. After a
total dose of 8 g liposomal amphotericin B, ﬂuconazole was
replaced by voriconazole (800 mg/d orally) and the patient was
discharged on December 5th, 2011. During the last 2-month
period the patient also received recombinant IFNg (200 mg)
subcutaneously thrice weekly. Because voriconazole was no
longer available he was treated with ﬂuconazole 400 mg from
March 21st until July 1st 2012. The patient’s blindness and loss of
hearing remained permanent. He was re-admitted to hospital on July
1st, 2012, due to progressive deterioration, clinical signs of intracra-
nial hypertension, seizures and papilledema. This improved slightly
after CSF puncture but after seven days receiving amphotericin B
deoxycholate (1 mg/kg/day) and ﬂuconazole 800mg/d he died on
July 8th, 2012, one year after the start of the clinical presentation of
the disease. An autopsy was not performed.
Identiﬁcation of the isolated yeasts as C. gattii was performed
by urease, inositol fermentation test and growth on canavanine-
glycine bromothymol blue (CGB) agar to differentiate C. neofor-
mans from C. gattii. Molecular identiﬁcation as C. gattii genotype
AFLP5 was done by using ampliﬁed fragment length polymorphism
(AFLP) ﬁngerprinting, as described previously [7,8]. The mating-
type was determined using a conventional PCR using STE12a- and
STE12a-speciﬁc primers [8] that revealed the presence of the
mating-type a allele for both isolates. The two Cuban C. gattii
AFLP5 isolates were sequenced for the seven nuclear loci CAP10,
GPD1, IGS1, LAC1, MPD1, PLB1 and TEF1 to compare them to the
data of other isolates with the genotype AFLP5, as published by
Hagen et al. (2012) and Byrnes et al. (2011) [3,9]. Sequences were
deposited in Genbank and can be accessed via the accession
numbers KC424622–KC424635. Isolates were deposited in the
CBS Fungal Biodiversity collection in Utrecht, the Netherlands as
CBS 12755 (CUBA 250) and CBS 12754 (CUBA 350). A bootstrap
Maximum Likelihood phylogenetic analysis was performed using
the settings as being used for a previously published C. gattii MLST
study [3] (Fig. 1).
3. Discussion
C. gattii differs from the more commonly isolated C. neofor-
mans in clinical aspects, ecological niche and genetic makeup.
Unlike C. neoformans, it most often affects immunocompetent
patients exposed to an environmental source causing pulmonary
and cerebral infections. Furthermore C. gattii is known to be more
resistant to antifungal agents. In the Caribbean, cryptococcosis
appears to be a relatively rare disease with an estimated 7800
new patients each year [10]. In Cuba, the disease was ﬁrst
reported in the early 1950s [11]. Since then sporadic cases were
associated with alcoholism, organ transplantations and immuno-
logical disorders. In 1986, with the beginning of the AIDS
epidemic in Cuba, the amount of individuals suffering from
cryptococcosis had increased over the years with an average of
eight new cases each year [12]. This might still be an under-
representation since a retrospective autopsy study of HIV/AIDS
patients performed during a 10-year period showed that disse-
minated or central nervous system cryptococcosis was a serious
and common disorder in 29% of the cases [13]. The clinical
presentation of cryptococcal infection varies from asymptomatic
pulmonary colonization to severe pneumonia with respiratory
failure and life-threatening meningitis [14,15]. Mostly infections
due to C. gattii genotypes AFLP4 and AFLP6 usually occurs in
patients without detectable predisposing factors while genotypes
AFLP5, AFLP7 and AFLP10 appear to be associated with an
impaired immune system (mainly AIDS, but also any other
immunosuppressive condition including solid organ transplanta-
tion) which is similar to C. neoformans [3,16]. Interestingly none
of these underlying diseases, previously associated with C. gattii
AFLP5 infection, could be demonstrated in our patient.
About 65%–77% of cases with C. gattii infections presents
more often with lung involvement [1]. Initial symptoms of our
patient ﬁtted with a community-acquired pneumonia and sputum
cultures only demonstrated Klebsiella. It might be hypothesized
that the development of a community-acquired pneumonia could
generate appropriated conditions favoring rapid multiplication and
dissemination of C. gattii from its dormant state. Cryptococcal
Table 1














12/7/2011 40 480 2.6 70 (þ) C. gattii
20/7/2011 35 171 2.4 215 (þ) C. gattii
25/8/2011 32 40.2 3.4 17.5 (þ) ()
5/9/2011 28 20 3.8 12 (þ) ()
19/9/2011 25 30 3.8 10 (þ) ()
3/10/2011 26 35 4 11 (þ) ()
13/10/2011 38 28 4.18 13 (þ) ()
23/10/2011 25 17.8 3.49 10 (þ) ()
9/11/2011 35 17.8 3.49 10 (þ) ()
5/12/2011 22 38 4.1 13.5 (þ) ()
1/7/2012 50 45 2.5 15 (þ) ()
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infection involves any part of the central nervous system and leads
to a wide spectrum of neurological symptoms such as headache,
altered consciousness, seizures, and cranial nerve palsies. Seaton
et al. [17] reviewed the ophthalmic ﬁndings in 82 immunocompe-
tent patients in whom C. gattii was involved. A high rate of visual
loss was observed in 52.6% of survivors similar what had occurred
in our patient.
Environmental exposure is known to be the dominant risk
factor for C. gattii infection, but so far all pathogenic clinical and
environmental Cryptococcus isolates from Cuba have been identi-
ﬁed as C. neoformans var. grubii [5]. However a single case of a
fatal veterinary C. gattii genotype AFLP4 infection was described
recently in a cheetah imported from South Africa. Molecular
epidemiologic studies strongly suggested that the animal was
not infected in Cuba, but most likely in Africa [18]. It has been
demonstrated before that C. gattii infections can be imported
subclinically and reactivate after being dormant for many
years [3]. There are three main arguments that support the
hypothesis that our patient had a dormant infection when he
returned to Cuba from Central America. First, there is no evidence
suggesting environmental presence of this species despite multi-
ple attempts to recover C. gattii from plants, trees and cacti in
Cuba [6], which is in strong contrast to for example India where
C. gattii can be isolated from up to 50% of investigated trees [16].
Secondly, it has been ample demonstrated that the time interval
between exposure to C. gattii and the development of the disease
is highly variable; at one extreme, acute infection have been
reported while reactivation of long silent subclinical infections is
also possible depending of the immunological status of the
patient [3,19]. We have no indication that a hereditary immune
disorder might have been involved but there is in vitro evidence
that clinical C. gattii isolates induced a more pronounced inﬂam-
matory response compared to other Cryptococcus species and
environmental C. gattii [20]. This might explain the severe
immunopathology seen in human (and animal) C. gattii infections.
And ﬁnally, molecular biological characterization showed that the
strain belonged to C. gattii genotype AFLP5. Although this geno-
type was originally reported from India and the USA, current
literature show that it has spread throughout Latin-American
countries (Argentina, Brazil, Colombia, Guatemala Mexico, and
Venezuela), the west coast of the USA., as well as over Asia and
Australia [3,16]. Comparison with a large C. gattii genotype AFLP5
MLST dataset [3,9] yielded a high similarity degree to strains from
clinical and environmental sources in Colombia. The patient’s
travel history to Central America suggests acquisition during this
time period.
The neurological picture in conjunction with the presence of
yeasts in the CSF let to suspect cryptococcal infection in our
patient initiating treatment according to management guidelines
[21] and availability of drugs. For meningoencephalitis and
disseminated disease due to C. gattii, recommended induction,
consolidation, and suppressive treatment are basically the same
as for C. neoformans. Because C. gattii infection is associated with
more neurological complications and delayed response to ther-
apy, as demonstrated in this case, a longer course of therapy,
increasing dose and/or recombinant IFNg as salvage therapy for
patients unresponsive to multiple antifungal drugs has been
suggested [21]. The latter salvage therapy was successful in
patients with C. neoformans infections [22]. For persistent and
relapse isolates it is highly recommended to look for changes in
the MIC from the original isolate (Z3-dilution difference suggests
development of direct drug resistance) [13,21]. Unfortunately,
although the direct examination of CSF stayed positive during the
whole disease course, cultures remained negative. Our case is a
quick alert to suspect C. gattii AFLP5 infection also in HIV negative
patients, to consider the growing possibility of imported
Fig. 1. A 1000 bootstrap Maximum Likelihood phylogenetic analysis of the two
Cuban strains (CBS 12755 and CBS 12754), compared to C. gattii AFLP5 strains
from previously published MLST studies [3,9]. Both Cuban strains (marked in red)
clustered together with clinical and environmental strains from Colombia.
Numbers next to branches represent bootstrap valuesZ75. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
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infections from endemic regions and the need for more effective
alternatives for treating this mycosis.
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